Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q02556
UPID:
IRF8_HUMAN
Alternative names:
Interferon consensus sequence-binding protein
Alternative UPACC:
Q02556; A0AV82
Background:
Interferon regulatory factor 8 (IRF8), also known as Interferon consensus sequence-binding protein, plays a pivotal role in immune response regulation. It binds specifically to the regulatory regions of type I interferon and MHC class I genes, influencing transcription. IRF8's involvement extends to dendritic cell differentiation, macroautophagy in dendritic cells, and repressing osteoclast differentiation.
Therapeutic significance:
IRF8's critical role in immune system regulation and its direct association with Immunodeficiency 32A and 32B, diseases characterized by susceptibility to infections and immunodeficiency, underscores its potential as a target for therapeutic intervention. Understanding IRF8's mechanisms could lead to novel treatments for these immunodeficiencies.